The New England journal of medicine · 2016 · Clinical trial · PMID 27633186
All interactive lessonsSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. Once-Weekly Semaglutide in Adults with Overweight or Obesity. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
IW Interactive Learning Engine · About 5 minutes
GLP-1: from receptor to evidence
0 of 6 steps completedSaved privately to this browser · 90 days
Step 1 · Explore
Start with the question
Semaglutide is a peptide GLP-1 analog used in several FDA-approved finished medications. Product names, formulations, indications and eligible populations differ. Semaglutide is a peptide GLP-1 analog used in several FDA-approved finished medications. Product names, formulations, indications and eligible populations differ.
Learning request limit reached. Please try again later.
Sources behind this lesson
The New England journal of medicine · 2021 · Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't · PMID 33567185
Verified sample: 1,961 · Adults with overweight or obesity without diabetes
Greater average weight reduction at 68 weeks; gastrointestinal effects were common.
Limitations: Product-, population- and protocol-specific; does not imply suitability for an individual.
The New England journal of medicine · 2023 · Clinical trial · PMID 37952131
Your scientific classroom
Ask the IW Science Instructor
Basic level · Published sources only · AI evidence check
Ask about general science. Do not enter names, personal health details or medication lists. This is not a clinical consultation. Discussion stays in this browser’s private learning session for up to 90 days.
IW Interactive Learning Engine · Adapted from stable OpenMAIC v1.2.1. Open-source license
Education only. Confidence labels are not formal systematic evidence grades. No patient record is used.
Education only. Confidence labels are not formal systematic evidence grades. No patient record is used.